Table 1.

Antiproliferative properties of the synthesized agents, curcumin, 5-fluorouracil and Sunitinib.

Entry	Compd.	IC50 ± SE, μM (SI)a
		A431	MCF7	HCT116	RPE1
1	5a	4.486 ± 0.41 (2.4)	4.736 ± 0.38 (2.25)	4.722 ± 0.42 (2.25)	10.64 ± 1.04
2	5b	2.125 ± 0.19 (3.9)	5.764 ± 0.47 (1.44)	5.097 ± 0.51 (1.63)	8.30 ± 0.71
3	5c	1.208 ± 0.11 (7.3)	2.806 ± 0.26 (3.15)	0.986 ± 0.08 (8.96)	8.83 ± 0.68
4	5d	0.986 ± 0.08 (9.8)	4.583 ± 0.39 (2.11)	3.597 ± 0.29 (2.69)	9.68 ± 0.57
5	5e	0.639 ± 0.07 (15.5)	6.000 ± 0.50 (1.65)	2.556 ± 0.18 (3.87)	9.89 ± 0.75
6	5f	6.042 ± 0.62 (1.6)	5.375 ± 0.51 (1.84)	6.083 ± 0.49 (1.63)	9.89 ± 0.66
7	5 g	0.973 ± 0.07 (10.6)	4.972 ± 0.42 (2.08)	2.389 ± 0.21 (4.32)	10.32 ± 1.10
8	5 h	0.472 ± 0.02 (18.3)	3.986 ± 0.36 (2.16)	1.333 ± 0.09 (6.47)	8.62 ± 0.72
9	5i	2.153 ± 0.15 (8.8)	5.583 ± 0.52 (3.41)	9.255 ± 0.61 (2.06)	19.04 ± 0.99
10	5j	2.514 ± 0.18 (3.7)	4.500 ± 0.39 (2.06)	2.625 ± 0.19 (3.53)	9.26 ± 0.75
11	5 k	0.417 ± 0.03 (18.6)	4.069 ± 0.33 (1.91)	1.972 ± 0.17 (3.94)	7.77 ± 0.56
12	5 l	0.667 ± 0.07 (10.8)	4.153 ± 0.37 (1.74)	1.153 ± 0.13 (6.27)	7.23 ± 0.49
13	5 m	3.811 ± 0.29 (1.9)	5.056 ± 0.45 (1.43)	5.944 ± 0.46 (1.22)	7.23 ± 0.51
14	5n	0.444 ± 0.04 (17.7)	4.389 ± 0.40 (1.79)	1.486 ± 0.17 (5.30)	7.87 ± 0.62
15	5o	0.431 ± 0.03 (16.3)	2.653 ± 0.22 (2.65)	0.750 ± 0.06 (9.36)	7.02 ± 0.45
16	5p	6.250 ± 0.49 (3.2)	6.250 ± 0.61 (3.18)	6.383 ± 0.44 (3.12)	19.89 ± 1.21
17	Curb	NTd	16.00 ± 2.04	38.25 ± 2.36	NTd
18	5-FUc	23.44 ± 2.09	3.15 ± 0.44	20.43 ± 1.99	---
19	Sunitinib	---	3.97 ± 0.32	9.67 ± 0.22	---

^aSI (selectivity index) = IC₅₀ of the normal cell line (RPE1) relative to that of the cancer cell, ^bCur = curcumin [15], [16], ^c5-FU = 5-flurouracil [15], [16], ^dNT = not tested.